Immunitas Therapeutics, Inc.

Immunitas Therapeutics, Inc. is a US-based biotechnology company focused on developing innovative therapies for cancer and autoimmune diseases through cutting-edge monoclonal antibody technology. Founded in 2019 and headquartered in Waltham, US, Immunitas Therapeutics is engaged in the development of therapeutics targeting cancer and autoimmune disorders. The company was co-founded by Karl Wittrup and Lea Hachigian and has received funding through two deals, with the most recent being a Series B round in August 2021, raising USD 29.

00 mn with Agent Capital as the lead investor. Immunitas Therapeutics operates independently without any known parent companies or subsidiaries. Immunitas Therapeutics specializes in developing innovative therapeutics aimed at treating cancer and autoimmune diseases. Its primary product, IMT-009, is an anti-CD161 monoclonal antibody currently in clinical trials for patients with refractory tumors, including those with MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer.

Additionally, the company is working on a novel therapeutic targeting the CD161-CLEC2D pathway for autoimmune diseases, serving oncologists and healthcare providers in North America and Europe. Immunitas Therapeutics generates revenue primarily through clinical trials and the development of proprietary immuno-oncology and autoimmune therapies. The company collaborates with research institutions and pharmaceutical firms, facilitating agreements related to product development and commercialization. IMT-009 plays a crucial role in its revenue strategy as it advances through clinical evaluations, with pricing structures aligned to industry standards.

Following the recent Series B funding of USD 29. 00 mn in August 2021, Immunitas Therapeutics intends to utilize these resources to advance its lead program, IMT-009, into clinical trials aimed at treating both solid tumors and hematological malignancies. The company is also exploring opportunities for product launches and market expansions, focusing on enhancing its presence in North America and Europe to address unmet medical needs in oncology and autoimmune sectors.